Interesting Images68Ga-DOTATATE and 18F-FDG PET/CT for the Management of Esthesioneuroblastoma of the Sphenoclival RegionDadgar, Habibollah PhD∗; Norouzbeigi, Nasim MD∗; Ahmadzadehfar, Hojjat MD, MSc†,‡; Assadi, Majid MD§Author Information From the ∗Cancer Research Center, Razavi Hospital, Imam Reza International University, Mashhad, Iran †Department of Nuclear Medicine, Klinikum Westfalen, Dortmund ‡Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany §The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Bushehr, Iran. Received for publication December 17, 2019; revision accepted April 26, 2020. Conflicts of interest and sources of funding: none declared. Correspondence to: Majid Assadi, MD, The Persian Gulf Nuclear Medicine Research Center, Department of Molecular Imaging and Radionuclide Therapy, Bushehr Medical University Hospital, Bushehr University of Medical Sciences, Moallem Street, Bushehr, Iran. E-mail: firstname.lastname@example.org; email@example.com. Clinical Nuclear Medicine: August 2020 - Volume 45 - Issue 8 - p e363-e364 doi: 10.1097/RLU.0000000000003133 Buy Metrics Abstract We present a 48-year-old woman with an olfactory neuroblastoma who was referred for accurate staging using PET/CT. The 68Ga-DOTATATE PET/CT showed a 51 × 32-mm mass with an SUVmax of 7.59 in the sphenoidal sinuses, whereas radiotracer uptake on 18F-FDG PET/CT was similar to that of brain tissue. 68Ga-DOTATATE PET/CT might be especially useful in regions with difficult tumor visualization resulting from high background, such as brain tissue. The results of this case may suggest that somatostatin receptor imaging in patients with esthesioneuroblastoma may facilitate the potential application of radiotheranostic agents for the treatment of this aggressive subtype of tumors. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.